Einfluss von Prä-/Comedikation und Kombinationspartnern auf die?Verträglichkeit einer onkologischen Therapie mit Bendamustin

Einfluss von Prä-/Comedikation und Kombinationspartnern auf die?Verträglichkeit einer onkologischen Therapie mit Bendamustin - BendaEVENTS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010592

Enrollment

750

Registered

2016-06-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C91.1 C85.9 C90.0

Interventions

Group 1: Doctor's will be asked about the patient therapy including pre-/comedication, primary diagnosis and other treatment related data

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: adults (=18 years), the doctor's decision for the prescribed therapy falls individually prior to inclusion in the NIS, Bendamustine Ribosepharm is used according to the prescribing information.

Exclusion criteria

Exclusion criteria: <18 years (minors), patients not able to consent, pregnant patients

Design outcomes

Primary

Measure	Time frame
Influence of premedication on the side effects of cancer therapy with bendamustine	—

Secondary

Measure	Time frame
Influence of combination partners on the side effects of cancer therapy with bendamustine	—

Countries

Germany

Contacts

Public ContactHayssam Zakaria

NewConceptOncology GmbH

zakaria@n-c-o.de0511 76355 123

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026